Insilico Medicine (HKG:3696) said it expects net profit of $33.5 million to $39.5 million for the first half of 2026, a turnaround from the $19.2 million net loss recorded a year earlier, according to a Hong Kong bourse filing on Thursday.
The firm attributed the turnaround to an expected 273% to 287% rise in revenue, to $102.5 million to $106.5 million, up from $27.5 million in the prior-year period.
Shares of the company were up nearly 7% in recent morning trade.